![](https://conferences.medicom-publishers.com/wp-content/uploads/2021/03/ONCO_StefanRauh-scaled-e1615476035796-743x1024.jpg)
ESMO 2023
Featured articles
![](https://conferences.medicom-publishers.com/wp-content/uploads/2021/03/ONCO_StefanRauh-scaled-e1615476035796-743x1024.jpg)
![](https://conferences.medicom-publishers.com/wp-content/uploads/2023/11/Witold-Rzyman-foto-source-iaslc.org_.jpg)
The importance of detecting early NSCLC
![](https://conferences.medicom-publishers.com/wp-content/uploads/2023/06/Medicom-Podcast-_-beeldmerk_white2.png)
CONTENTS
Online First
Breast Cancer
Benefit of pembrolizumab in TNBC remains after 5 years of follow-up
![](https://conferences.medicom-publishers.com/wp-content/uploads/2023/12/Figure-Pathological-complete-response-1024x594.png)
Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer
Long-term air pollution exposure at both residential and workplace locations increases breast cancer risk
Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy
Colorectal Cancer
Neoadjuvant nivolumab/relatlimab demonstrates 100% pathological response in MMRd colon cancer
Selective KRASG12C inhibitor sotorasib leads to superior PFS in colorectal cancer
![](https://conferences.medicom-publishers.com/wp-content/uploads/2023/12/Figure-CtDNA-status-linked-to-disease-free-1024x733.png)
Postoperative ctDNA predicts survival in colorectal cancer
Overall survival in patients with initially unresectable colorectal liver metastases does not depend on choice of induction regimen
Lung Cancer
![](https://conferences.medicom-publishers.com/wp-content/uploads/2023/12/Figure-EFS-per-blinded-independent-1024x644.png)
Perioperative nivolumab boosts event-free survival in NSCLC
Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC
Dato-DXd outperforms docetaxel in previously treated patients with metastatic NSCLC
First-line and second-line benefit of amivantamab in advanced, EGFR-mutated NSCLC
Upper Gastro-Intestinal Cancer
Perioperative durvalumab/FLOT improves pCR in gastric cancer
![](https://conferences.medicom-publishers.com/wp-content/uploads/2023/12/Figure-Overall-survival-does-not-change-1024x734.png)
Active surveillance after neoadjuvant chemoradiotherapy in oesophageal cancer
FOLFIRINOX equals gemcitabine-based chemoradiotherapy in neoadjuvant setting for pancreatic cancer
Modified FLOT regime outperforms FOLFOX in advanced/metastatic gastric/gastroesophageal junction adenocarcinoma
Melanoma
Lifileucel induces a durable response in heavily pretreated mucosal melanoma
![](https://conferences.medicom-publishers.com/wp-content/uploads/2023/12/Figure-Overall-response-and-disease-control-rates-1024x318.png)
Darovasertib/crizotinib combination: a potential first-line therapy in metastatic uveal melanoma
Genito-Urinary Cancers
![](https://conferences.medicom-publishers.com/wp-content/uploads/2023/12/Figure-Overall-survival-was-reduced-by-53-1024x780.png)
Two potential new first-line standards of care in metastatic urothelial cancer
LuPSMA and enzalutamide: a promising combination
No benefit of erdafitinib over pembrolizumab in urothelial cancer second-line therapy
Gynaecological Cancers
Addition of atezolizumab to chemotherapy and maintenance PARP inhibitor has no benefit in ovarian cancer
Short-induction chemotherapy improves survival in advanced cervical cancer
Neoadjuvant immune checkpoint blockade safe and effective in MMRd endometrial cancer
Featured Interviews
![](https://conferences.medicom-publishers.com/wp-content/uploads/2023/11/1686664267300-e1700492465793.jpg)
Can radiotracers predict response to PD-L1 inhibitors in early NSCLC?
![](https://conferences.medicom-publishers.com/wp-content/uploads/2023/11/Witold-Rzyman-foto-source-iaslc.org_.jpg)